Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Cantor Fitzgerald pharmaceuticals analysts hold analyst/industry conference call » 10:43
06/29/20
06/29
10:43
06/29/20
10:43
AMRN

Amarin

$6.67 /

-0.025 (-0.37%)

Pharmaceuticals Analysts,…

Pharmaceuticals Analysts, along with Zachary Silbersher, the founding partner of Kroub, Silbersher & Kolmykov (KSK), PLLC, discuss the likelihood that Amarin will win its appeal for Vascepa on an Analyst/Industry conference call to be held on June 29 at 11 am.

ShowHide Related Items >><<
AMRN Amarin
$6.67 /

-0.025 (-0.37%)

AMRN Amarin
$6.67 /

-0.025 (-0.37%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Jefferies
Jefferies sees growing reasons to believe Amarin may win Vascepa appeal
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
AMRN Amarin
$6.67 /

-0.025 (-0.37%)

  • 19
    Jul
AMRN Amarin
$6.67 /

-0.025 (-0.37%)

AMRN Amarin
$6.67 /

-0.025 (-0.37%)

AMRN Amarin
$6.67 /

-0.025 (-0.37%)

Hot Stocks
Intercept plunges, drags down some NASH peers after CRL from FDA » 07:26
06/29/20
06/29
07:26
06/29/20
07:26
ICPT

Intercept

$77.56 /

-2.09 (-2.62%)

, CBAY

CymaBay

$3.74 /

-0.11 (-2.86%)

, NGM

NGM Biopharmaceuticals

$22.37 /

-0.53 (-2.31%)

, MDGL

Madrigal Pharmaceuticals

$108.04 /

-2.46 (-2.23%)

, NVO

Novo Nordisk

$66.03 /

-1.18 (-1.76%)

, GNFT

Genfit

$5.57 /

-0.42 (-7.01%)

, LLY

Eli Lilly

$162.91 /

-0.09 (-0.06%)

, ALNY

Alnylam

$151.68 /

-4.765 (-3.05%)

Shares of Intercept…

Shares of Intercept Pharmaceuticals (ICPT) have plunged in early morning trading after the company announced that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for obeticholic acid for the treatment of fibrosis due to nonalcoholic steatohepatitis, or NASH. Based on the data the FDA has reviewed to date, the Agency has determined that the predicted benefit of OCA based on a surrogate histopathologic endpoint remains uncertain and does not sufficiently outweigh the potential risks to support accelerated approval for the treatment of patients with liver fibrosis due to NASH, Intercept tells investors. Following the announcement, shares of Intercept are down $25.82, or 33%, to $51.67 in pre-market trading. A number of other companies working on NASH treatments are also moving lower, with CymaBay (CBAY) down about 3% and NGM Biopharmaceuticals (NGM) fractionally lower. Other companies exploring NASH treatments include Madrigal Pharmaceuticals (MDGL), Novo Nordisk (NVO), Genfit (GNFT), Eli Lilly (LLY), and Alnylam Pharmaceuticals (ALNY).

ShowHide Related Items >><<
NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

NGM NGM Biopharmaceuticals
$22.37 /

-0.53 (-2.31%)

MDGL Madrigal Pharmaceuticals
$108.04 /

-2.46 (-2.23%)

LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

ICPT Intercept
$77.56 /

-2.09 (-2.62%)

GNFT Genfit
$5.57 /

-0.42 (-7.01%)

CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

ALNY Alnylam
$151.68 /

-4.765 (-3.05%)

ICPT Intercept
$77.56 /

-2.09 (-2.62%)

06/25/20 H.C. Wainwright
Intercept initiated with a Neutral at H.C. Wainwright
06/04/20 BMO Capital
Intercept initiated with an Outperform at BMO Capital
05/22/20 B. Riley FBR
Intercept weakness on 'slight' delay should be bought, says B. Riley FBR
05/22/20 Raymond James
Intercept downgraded at Raymond James after OCA NDA is postponed
CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

06/22/20 B. Riley FBR
CymaBay risk/reward favorable into FDA engagement, says B. Riley FBR
05/26/20 H.C. Wainwright
CymaBay upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Citi
CymaBay price target raised to $7 from $1.60 at Citi
05/12/20 B. Riley FBR
CymaBay upgraded to Buy from Neutral at B. Riley FBR
NGM NGM Biopharmaceuticals
$22.37 /

-0.53 (-2.31%)

06/04/20 BMO Capital
NGM Biopharmaceuticals initiated with an Outperform at BMO Capital
05/06/20 Stifel
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals
04/06/20 Raymond James
NGM Biopharmaceuticals initiated with a Strong Buy at Raymond James
03/31/20 H.C. Wainwright
Akero's BALANCED study results 'quite impressive,' says H.C. Wainwright
MDGL Madrigal Pharmaceuticals
$108.04 /

-2.46 (-2.23%)

06/04/20 BMO Capital
Madrigal Pharmaceuticals initiated with a Market Perform at BMO Capital
05/22/20 B. Riley FBR
Madrigal Pharmaceuticals price target raised to $174 from $134 at B. Riley FBR
05/08/20 H.C. Wainwright
Madrigal Pharmaceuticals price target lowered to $168 from $215 at H.C. Wainwright
05/06/20 Goldman Sachs
Goldman says Novo Nordisk NASH data a 'clear positive' for Intercept
NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
05/11/20
Fly Intel: Top five analyst downgrades
GNFT Genfit
$5.57 /

-0.42 (-7.01%)

06/25/20 BofA
Genfit's NASH program 'all but done,' says BofA, initiating with an Underperform
06/25/20 BofA
Genfit initiated with an Underperform at BofA
05/13/20 Bryan Garnier
Genfit downgraded to Neutral from Buy at Bryan Garnier
LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/17/20 JPMorgan
Eli Lilly price target raised to $190 from $175 at JPMorgan
06/16/20
Fly Intel: Top five analyst upgrades
06/16/20 Guggenheim
Guggenheim upgrades Eli Lilly to Buy after 'transformational' breast cancer data
ALNY Alnylam
$151.68 /

-4.765 (-3.05%)

06/08/20 Cantor Fitzgerald
Alnylam lumasiran data reinforces confidence in efficacy, says Cantor Fitzgerald
06/07/20 Stifel
No surprises in 'positive' Alnylan Lumasiran ILLUMINATE-A data, says Stifel
05/12/20 RBC Capital
Alnylam initiated with a Sector Perform at RBC Capital
05/07/20 Oppenheimer
Alnylam price target raised to $162 from $140 at Oppenheimer
NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

NGM NGM Biopharmaceuticals
$22.37 /

-0.53 (-2.31%)

MDGL Madrigal Pharmaceuticals
$108.04 /

-2.46 (-2.23%)

LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

ICPT Intercept
$77.56 /

-2.09 (-2.62%)

CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

ALNY Alnylam
$151.68 /

-4.765 (-3.05%)

  • 11
    Dec
NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

GNFT Genfit
$5.57 /

-0.42 (-7.01%)

ALNY Alnylam
$151.68 /

-4.765 (-3.05%)

NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

NGM NGM Biopharmaceuticals
$22.37 /

-0.53 (-2.31%)

LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

ICPT Intercept
$77.56 /

-2.09 (-2.62%)

CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

NGM NGM Biopharmaceuticals
$22.37 /

-0.53 (-2.31%)

LLY Eli Lilly
$162.91 /

-0.09 (-0.06%)

CBAY CymaBay
$3.74 /

-0.11 (-2.86%)

Hot Stocks
Novo Nordisk reports Rybelsus approved in Japan for treatment of type 2 diabetes » 07:03
06/29/20
06/29
07:03
06/29/20
07:03
NVO

Novo Nordisk

$66.03 /

-1.18 (-1.76%)

, MRK

Merck

$75.16 /

-1.43 (-1.87%)

Novo Nordisk (NVO)…

Novo Nordisk (NVO) announced that the Japanese Ministry of Health, Labour and Welfare has approved Rybelsus, which it calls "the first and only oral glucagon-like peptide-1 receptor agonist in a tablet," for the treatment of adults with type 2 diabetes. Novo Nordisk will now initiate reimbursement negotiations and expects to launch Rybelsus in Japan thereafter. Novo Nordisk and Merck (MRK), known as MSD outside the United States and Canada, will be co-promoting Rybelsus in Japan.

ShowHide Related Items >><<
NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

MRK Merck
$75.16 /

-1.43 (-1.87%)

NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
05/11/20
Fly Intel: Top five analyst downgrades
MRK Merck
$75.16 /

-1.43 (-1.87%)

06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/23/20 Morgan Stanley
Merck's COVID-19 antiviral candidate underappreciated, says Morgan Stanley
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

MRK Merck
$75.16 /

-1.43 (-1.87%)

NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

MRK Merck
$75.16 /

-1.43 (-1.87%)

NVO Novo Nordisk
$66.03 /

-1.18 (-1.76%)

MRK Merck
$75.16 /

-1.43 (-1.87%)

MRK Merck
$75.16 /

-1.43 (-1.87%)

Over a week ago
Conference/Events
Healthcare Financial Management Association to hold a virtual conference » 08:56
06/24/20
06/24
08:56
06/24/20
08:56
MTBC

MTBC

$8.50 /

-0.26 (-2.97%)

, NVZMY

Novozymes

$0.00 /

+ (+0.00%)

, NVS

Novartis

$90.49 /

-0.09 (-0.10%)

, NVAX

Novavax

$69.66 /

+3.72 (+5.64%)

, MRK

Merck

$77.11 /

+0.4 (+0.52%)

, LOGI

Logitech

$62.73 /

-0.32 (-0.51%)

, REGN

Regeneron

$628.72 /

+0.81 (+0.13%)

, RDY

Dr. Reddy's

$54.33 /

+1.04 (+1.95%)

, FREQ

Frequency Therapeutics

$22.68 /

-0.47 (-2.03%)

, RCKT

Rocket Pharmaceuticals

$22.80 /

+0.275 (+1.22%)

, TRVI

Trevi Therapeutics

$5.71 /

+0.26 (+4.77%)

, CSU

Capital Senior Living

$0.76 /

-0.037 (-4.64%)

, NVO

Novo Nordisk

$67.93 /

-0.005 (-0.01%)

HFMA 2020 Digital Annual…

HFMA 2020 Digital Annual Conference will be held on June 24. Webcast Link

ShowHide Related Items >><<
TRVI Trevi Therapeutics
$5.71 /

+0.26 (+4.77%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

RCKT Rocket Pharmaceuticals
$22.80 /

+0.275 (+1.22%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MTBC MTBC
$8.50 /

-0.26 (-2.97%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

FREQ Frequency Therapeutics
$22.68 /

-0.47 (-2.03%)

CSU Capital Senior Living
$0.76 /

-0.037 (-4.64%)

MTBC MTBC
$8.50 /

-0.26 (-2.97%)

06/22/20 H.C. Wainwright
MTBC upgraded to Buy from Neutral at H.C. Wainwright
06/02/20 Ladenburg
MTBC initiated with a Buy at Ladenburg
03/03/20
LD Micro to hold a virtual conference
03/02/20
Fly Intel: Top five analyst downgrades
NVZMY Novozymes
$0.00 /

+ (+0.00%)

05/12/20 Credit Suisse
Novozymes downgraded to Underperform from Outperform at Credit Suisse
04/01/20 Goldman Sachs
Novozymes downgraded to Sell from Buy at Goldman Sachs
03/13/20
Goldman Sachs to hold a conference
01/14/20 Exane BNP Paribas
Novozymes downgraded to Neutral from Outperform at Exane BNP Paribas
NVS Novartis
$90.49 /

-0.09 (-0.10%)

06/24/20 Morgan Stanley
Novartis' syringe suit not a material threat to Regeneron, says Morgan Stanley
06/16/20 Guggenheim
Guggenheim upgrades Alcon to Buy on strong momentum exiting shutdown
06/15/20
Fly Intel: Top five analyst upgrades
06/15/20 Citi
Novartis upgraded to Buy from Neutral at Citi
NVAX Novavax
$69.66 /

+3.72 (+5.64%)

06/19/20 Cantor Fitzgerald
Novavax price target raised to $88 from $45 at Cantor Fitzgerald
06/05/20
Fly Intel: Top five analyst upgrades
06/05/20 JPMorgan
JPMorgan upgrades Novavax to Neutral despite 'shaky fundamentals'
06/05/20 B. Riley FBR
Novavax price target raised to $74 from $61 at B. Riley FBR
MRK Merck
$77.11 /

+0.4 (+0.52%)

06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
06/23/20 Morgan Stanley
Merck's COVID-19 antiviral candidate underappreciated, says Morgan Stanley
06/23/20 Guggenheim
Immunomedics could be M&A fit for several large-cap drugmakers, says Guggenheim
06/12/20 Wolfe Research
Merck downgraded to Peer Perform from Outperform at Wolfe Research
LOGI Logitech
$62.73 /

-0.32 (-0.51%)

06/24/20 Wedbush
Logitech downgraded to Neutral at Wedbush with limited multiple expansion ahead
06/24/20 Wedbush
Logitech downgraded to Neutral from Outperform at Wedbush
06/04/20 DA Davidson
Logitech price target raised to $70 from $64 at DA Davidson
05/21/20
Fly Intel: Top five analyst downgrades
REGN Regeneron
$628.72 /

+0.81 (+0.13%)

06/24/20 Credit Suisse
Regeneron price target raised to $700 from $605 at Credit Suisse
06/18/20 Piper Sandler
AbbVie atopic dermatitis data a postive, says Piper Sandler
06/15/20 Piper Sandler
Piper says 'meaningfully above-consensus estimates' for Dupixent are right
RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
04/21/20 Nomura Instinet
Dr. Reddy's price target raised to INR 4,426 from INR 3,684
03/31/20 Goldman Sachs
Goldman downgrades Amarin, cuts target to $4 from $27 after patent ruling
FREQ Frequency Therapeutics
$22.68 /

-0.47 (-2.03%)

05/18/20 JPMorgan
JPMorgan downgrades Frequency Therapeutics on unclear data timelines
05/18/20 JPMorgan
Frequency Therapeutics downgraded to Neutral from Overweight at JPMorgan
10/28/19 JPMorgan
Frequency Therapeutics initiated with an Overweight at JPMorgan
10/28/19 Cowen
Frequency Therapeutics initiated with an Outperform at Cowen
RCKT Rocket Pharmaceuticals
$22.80 /

+0.275 (+1.22%)

05/13/20 Piper Sandler
Rocket Pharmaceuticals programs look even more promising, says Piper Sandler
03/05/20 Piper Sandler
Piper sees 'substantial value' for Rocket from numerous trial readouts
12/09/19 Oppenheimer
Rocket Pharmaceuticals price target raised to $42 from $36 at Oppenheimer
12/06/19 Baird
Rocket Pharmaceuticals elevated to Fresh Pick, target raised to $41 at Baird
TRVI Trevi Therapeutics
$5.71 /

+0.26 (+4.77%)

CSU Capital Senior Living
$0.76 /

-0.037 (-4.64%)

09/03/19 Barclays
Capital Senior Living initiated with an Underweight at Barclays
NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
05/11/20
Fly Intel: Top five analyst downgrades
TRVI Trevi Therapeutics
$5.71 /

+0.26 (+4.77%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

RCKT Rocket Pharmaceuticals
$22.80 /

+0.275 (+1.22%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MTBC MTBC
$8.50 /

-0.26 (-2.97%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

FREQ Frequency Therapeutics
$22.68 /

-0.47 (-2.03%)

CSU Capital Senior Living
$0.76 /

-0.037 (-4.64%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

RDY Dr. Reddy's
$54.33 /

+1.04 (+1.95%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVO Novo Nordisk
$67.93 /

-0.005 (-0.01%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

REGN Regeneron
$628.72 /

+0.81 (+0.13%)

NVS Novartis
$90.49 /

-0.09 (-0.10%)

NVAX Novavax
$69.66 /

+3.72 (+5.64%)

MRK Merck
$77.11 /

+0.4 (+0.52%)

LOGI Logitech
$62.73 /

-0.32 (-0.51%)

FREQ Frequency Therapeutics
$22.68 /

-0.47 (-2.03%)

Options
Notable open interest changes for June 23rd » 08:55
06/23/20
06/23
08:55
06/23/20
08:55
AAPL

Apple

$359.08 /

+9.53 (+2.73%)

, AMRN

Amarin

$7.13 /

+0.22 (+3.18%)

, BAC

Bank of America

$24.62 /

-0.34 (-1.36%)

, AAL

American Airlines

$14.91 /

-1.085 (-6.78%)

Monday's total…

Monday's total option volume of 25.5 million contracts resulted in net open interest growth of 4.84 million calls and 3.73 million puts. Apple (AAPL), Amarin (AMRN), Bank of America (BAC) and American Airlines (AAL) saw the greatest growth. Top five new positions opened include 51k Ford (F) Aug-20 6 puts, 27k Amarin (AMRN) Sep-20 7 calls, 22k Amarin (AMRN) Sep-20 10 calls, 20k Amarin (AMRN) Sep-20 6 puts and 20k US Steel (X) Aug-20 7 puts.

ShowHide Related Items >><<
BAC Bank of America
$24.62 /

-0.34 (-1.36%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

AAPL Apple
$359.08 /

+9.53 (+2.73%)

AAL American Airlines
$14.91 /

-1.085 (-6.78%)

AAPL Apple
$359.08 /

+9.53 (+2.73%)

06/23/20 Credit Suisse
Apple launches at WWDC more incremental than thesis-changing, says Credit Suisse
06/23/20 Oppenheimer
Apple creating 'wide moat' for own ecosystem, says Oppenheimer
06/23/20 Goldman Sachs
Apple's revamped Mac rollout plans look aggressive, says Goldman Sachs
AMRN Amarin
$7.13 /

+0.22 (+3.18%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Jefferies
Jefferies sees growing reasons to believe Amarin may win Vascepa appeal
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
BAC Bank of America
$24.62 /

-0.34 (-1.36%)

06/11/20 BTIG
First Department ruling 'a significant positive' for Ambac Financial, says BTIG
06/05/20 Wells Fargo
Bank of America price target raised to $35 from $30 at Wells Fargo
04/16/20 DA Davidson
Bank of America price target raised to $26 from $24 at DA Davidson
04/16/20 BMO Capital
Bank of America price target lowered to $24 from $26 at BMO Capital
AAL American Airlines
$14.91 /

-1.085 (-6.78%)

06/17/20
Fly Intel: Top five analyst initiations
06/17/20 Seaport Global
American Airlines initiated with a Buy at Seaport Global
06/17/20 Cowen
American Airlines price target raised to $20 from $15 at Cowen
06/16/20 Stifel
United loyalty deal raises odds of survival without restructuring, says Stifel
BAC Bank of America
$24.62 /

-0.34 (-1.36%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

AAPL Apple
$359.08 /

+9.53 (+2.73%)

AAL American Airlines
$14.91 /

-1.085 (-6.78%)

  • 23
    Jun
BAC Bank of America
$24.62 /

-0.34 (-1.36%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

AAPL Apple
$359.08 /

+9.53 (+2.73%)

AAL American Airlines
$14.91 /

-1.085 (-6.78%)

BAC Bank of America
$24.62 /

-0.34 (-1.36%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

AAPL Apple
$359.08 /

+9.53 (+2.73%)

AAL American Airlines
$14.91 /

-1.085 (-6.78%)

BAC Bank of America
$24.62 /

-0.34 (-1.36%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

AAPL Apple
$359.08 /

+9.53 (+2.73%)

AAL American Airlines
$14.91 /

-1.085 (-6.78%)

AAPL Apple
$359.08 /

+9.53 (+2.73%)

Options
Unusual call flow in option market yesterday » 07:35
06/23/20
06/23
07:35
06/23/20
07:35
X

U.S. Steel

$8.05 /

-0.06 (-0.74%)

, AMRN

Amarin

$7.13 /

+0.22 (+3.18%)

Notable call activity was…

Notable call activity was cited Monday in US Steel (X) and Amarin (AMRN).

ShowHide Related Items >><<
X U.S. Steel
$8.05 /

-0.06 (-0.74%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

X U.S. Steel
$8.05 /

-0.06 (-0.74%)

06/09/20 GLJ Research
U.S. Steel upgraded to Hold from Sell at GLJ Research
03/23/20 BMO Capital
U.S. Steel price target lowered to $6 from $9 at BMO Capital
01/31/20 BMO Capital
U.S. Steel price target lowered to $10 from $14 at BMO Capital
01/14/20 Goldman Sachs
U.S. Steel reinstated with a Sell at Goldman Sachs
AMRN Amarin
$7.13 /

+0.22 (+3.18%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Jefferies
Jefferies sees growing reasons to believe Amarin may win Vascepa appeal
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
X U.S. Steel
$8.05 /

-0.06 (-0.74%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

X U.S. Steel
$8.05 /

-0.06 (-0.74%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

X U.S. Steel
$8.05 /

-0.06 (-0.74%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

X U.S. Steel
$8.05 /

-0.06 (-0.74%)

AMRN Amarin
$7.13 /

+0.22 (+3.18%)

Options
Double spread collar in Amarin opens bullish position » 12:00
06/22/20
06/22
12:00
06/22/20
12:00
AMRN

Amarin

$6.82 /

-0.095 (-1.37%)

Double spread collar in…

Double spread collar in Amarin opens bullish position. Shares little changed this morning near $6.80 with a 4-way spread on the ISE where a customer appears to have sold the Sep 5/6 put spread to buy the Sep 7/10 call spread a total of 20k times, opening on all legs. For the largest tranche of 15k, the net credit on the put spread was 27c and the debit on the call spread 77c, for a net debit of 50c, or about $1M on the package. Net delta on the package is nearly 670k shares, or 9% the average daily turnover in the name. Amarin shares dropped nearly 70% from over $13 to $4 on March 31 related to a court ruling. Today's trade could return a 500% gain to the buyer if shares were to return to double digit territory over the next three months.

ShowHide Related Items >><<
AMRN Amarin
$6.82 /

-0.095 (-1.37%)

AMRN Amarin
$6.82 /

-0.095 (-1.37%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Jefferies
Jefferies sees growing reasons to believe Amarin may win Vascepa appeal
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
AMRN Amarin
$6.82 /

-0.095 (-1.37%)

AMRN Amarin
$6.82 /

-0.095 (-1.37%)

AMRN Amarin
$6.82 /

-0.095 (-1.37%)

AMRN Amarin
$6.82 /

-0.095 (-1.37%)

Hot Stocks
Novo Nordisk says Phase 2 AM833 trial reached primary endpoint » 10:30
06/18/20
06/18
10:30
06/18/20
10:30
NVO

Novo Nordisk

$65.83 /

-0.92 (-1.38%)

Novo Nordisk announced…

Novo Nordisk announced the headline results from two clinical trials with a novel once-weekly subcutaneous amylin analogue, a Phase 2 monotherapy trial and a Phase 1 combination trial of AM833 and once-weekly subcutaneous semaglutide 2.4 mg. The 26-week blinded Phase 2 monotherapy trial with AM833 investigated safety, tolerability and efficacy for weight management in 706 people with obesity or overweight with at least one weight-related comorbidity. The patients were randomized to treatment with five different weekly doses of AM833, liraglutide 3.0 mg or placebo. Approximately 100 people were included in each treatment arm. The trial reached its primary endpoint by demonstrating a weight loss of 10.8% at week 26 with AM833 at the 4.5 mg dose, compared to a weight loss of 3.0 % with placebo, Novartis said in a statement. The treatment difference was statistically significant and AM833 appeared to have a safe and well-tolerated profile, the company added. The 20-week multiple ascending dose phase 1 trial investigated safety, tolerability, pharmacokinetics and weight loss potential of AM833 administrated in combination with semaglutide 2.4 mg in 80 people with obesity or overweight. After 20 weeks of treatment, participants receiving the highest dose lost an average of 17.1% body weight from a mean baseline body weight of 95.1 kg. The trial investigated the number of treatment-emergent adverse events and AM833 was well-tolerated, with the most common adverse events being gastrointestinal disorders including nausea and vomiting, according to Novartis.

ShowHide Related Items >><<
NVO Novo Nordisk
$65.83 /

-0.92 (-1.38%)

NVO Novo Nordisk
$65.83 /

-0.92 (-1.38%)

06/05/20 JPMorgan
JPMorgan backs Overweight on Novo Nordisk after STEP data
05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
05/11/20
Fly Intel: Top five analyst downgrades
NVO Novo Nordisk
$65.83 /

-0.92 (-1.38%)

NVO Novo Nordisk
$65.83 /

-0.92 (-1.38%)

NVO Novo Nordisk
$65.83 /

-0.92 (-1.38%)

Recommendations
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink » 09:12
06/17/20
06/17
09:12
06/17/20
09:12
AMRN

Amarin

$6.88 /

+0.03 (+0.44%)

, RDY

Dr. Reddy's

$53.06 /

-0.69 (-1.28%)

SVB Leerink analyst Ami…

SVB Leerink analyst Ami Fadia notes that Amarin (AMRN) has settled Vascepa patent litigation with Apotex. While the analyst doesn't believe the U.S. Vascepa patent litigation settlement with Apotex provides any readthrough on the strength of Amarin's case in the ongoing appeal versus Hikma and Dr. Reddy's (RDY), it consolidates the fate of Apotex with the other generic filers and gives Amarin greater clarity on how generic competition in the U.S. will shape up post the appeals ruling. Fadia thinks the settlement puts more at stake for Amarin, and reflects management doubling down on the strength of its appeal's case, although she doesn't disagree with the decision given the risk/reward on the appeal is heavily skewed to the upside. The analyst continues to assign a 20% Probability of Success that Amarin wins the appeal. Fadia has an Outperform rating on Amarin's shares.

ShowHide Related Items >><<
RDY Dr. Reddy's
$53.06 /

-0.69 (-1.28%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Jefferies
Jefferies sees growing reasons to believe Amarin may win Vascepa appeal
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
05/22/20 Roth Capital
Roth sees low likelihood of at-risk generic launch of Vascepa
RDY Dr. Reddy's
$53.06 /

-0.69 (-1.28%)

04/21/20 Nomura Instinet
Dr. Reddy's price target raised to INR 4,426 from INR 3,684
03/31/20 Goldman Sachs
Goldman downgrades Amarin, cuts target to $4 from $27 after patent ruling
03/13/20 Goldman Sachs
Amarin upgraded to Buy from Neutral at Goldman Sachs
RDY Dr. Reddy's
$53.06 /

-0.69 (-1.28%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

RDY Dr. Reddy's
$53.06 /

-0.69 (-1.28%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

Recommendations
Amarin settlement with Apotex an 'incremental positive,' says Stifel » 08:28
06/17/20
06/17
08:28
06/17/20
08:28
AMRN

Amarin

$6.88 /

+0.03 (+0.44%)

, RDY

Dr. Reddy's

$53.06 /

-0.69 (-1.28%)

, TEVA

Teva

$12.05 /

+0.55 (+4.78%)

Stifel analyst Derek…

Stifel analyst Derek Archila reiterates his Hold rating on Amarin (AMRN) shares after the company settled with Apotex regarding its ANDA application for generic Vascepa. Apotex cannot sell a generic version of Vascepa until August 2029, which is the same date as Amarin's settlement with Teva (TEVA), noted Archila. While this settlement with another generic ANDA filer is an "incremental positive," Archila doesn't see this a major stock moving catalyst since Apotex is not a party in the ongoing appeal of the district court's decision invalidating Vascepa's patents, he tells investors. He expects Amarin shares to remain range-bound until closer to the hearing on the Hikma and Dr. Reddy's (RDY) case later this year, added Archila.

ShowHide Related Items >><<
TEVA Teva
$12.05 /

+0.55 (+4.78%)

RDY Dr. Reddy's
$53.06 /

-0.69 (-1.28%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

06/08/20 Jefferies
Jefferies sees growing reasons to believe Amarin may win Vascepa appeal
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
05/22/20 Roth Capital
Roth sees low likelihood of at-risk generic launch of Vascepa
05/22/20 Roth Capital
Amarin selloff today a buying opportunity, says Roth Capital
RDY Dr. Reddy's
$53.06 /

-0.69 (-1.28%)

04/21/20 Nomura Instinet
Dr. Reddy's price target raised to INR 4,426 from INR 3,684
03/31/20 Goldman Sachs
Goldman downgrades Amarin, cuts target to $4 from $27 after patent ruling
03/13/20 Goldman Sachs
Amarin upgraded to Buy from Neutral at Goldman Sachs
02/26/20 H.C. Wainwright
H.C. Wainwright reiterates $51 price target on Amarin shares post Q4 results
TEVA Teva
$12.05 /

+0.55 (+4.78%)

06/08/20 Guggenheim
Emergent BioSolutions price target lowered to $87 from $101 at Guggenheim
06/01/20
Fly Intel: Top five analyst upgrades
06/01/20 SunTrust
Teva upgraded to Buy from Hold at SunTrust
06/01/20 SunTrust
Teva upgraded to Buy from Hold at SunTrust
TEVA Teva
$12.05 /

+0.55 (+4.78%)

RDY Dr. Reddy's
$53.06 /

-0.69 (-1.28%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

TEVA Teva
$12.05 /

+0.55 (+4.78%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

TEVA Teva
$12.05 /

+0.55 (+4.78%)

RDY Dr. Reddy's
$53.06 /

-0.69 (-1.28%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

TEVA Teva
$12.05 /

+0.55 (+4.78%)

AMRN Amarin
$6.88 /

+0.03 (+0.44%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.